Anal Cancer Clinical Trial
Official title:
Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men
Verified date | June 2011 |
Source | Laser Surgery Care |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
This study is designed to identify barriers that prevent men who have sex with men from
receiving doctor-recommended annual follow-up screenings for anal cancer. Men who are at the
highest risk for developing anal cancer will be asked to complete a brief questionnaire
(either via telephone or in writing). The questionnaire is designed to identify potential
barriers to care-seeking behavior including, relationship status, financial constraints,
highest level of education and knowledge about anal cancer and its precursors. The men who
agree to participate in the study will then be organized into groups based on their history
of coming in for follow-up screening visits after learning that they are at higher risk for
developing anal cancer. These groups include 1) men that have come in for regular screening
visits (at least once per year), 2) men who came in once and were then lost to follow-up, 3)
men who came in for more than one screening visit and were then lost to follow-up, and 4)
men who were previously lost to follow-up and then began coming in for screening again. By
comparing the men's responses across the different groups, we hope to uncover key barriers
and drivers to follow-up screenings for anal cancer.
The goal of this study is to evaluate the differences in questionnaire responses across
cohorts that may impact care-seeking behavior.
We hypothesize that:
- Patients who regularly comply with annual follow-up screening visits score higher on
questions assessing knowledge of HPV and anal cancer.
- Men in stable relationships are more likely to comply with annual screening visit
recommendations.
- Men who are educated by their primary care physicians about the importance of anal
cancer screenings have higher screening rates.
Status | Completed |
Enrollment | 195 |
Est. completion date | May 2008 |
Est. primary completion date | May 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - MSM patients in Dr. Stephen Goldstone's private surgical practice who previously tested positive for one of the known HPV subtypes (HPV types 6, 11, 16, 18, 31, 33 and 35) and developed condyloma and/or dysplasia in the anogenital region. Exclusion Criteria: - Failure to provide consent to participate in the telephone or written questionnaire. - Development of anal cancer. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Laser Surgery Care | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Laser Surgery Care | Merck Sharp & Dohme Corp. |
United States,
Truesdale MD, Goldstone SE. The fear factor: drivers and barriers to follow-up screening for human papillomavirus-related anal cancer in men who have sex with men. Int J STD AIDS. 2010 Jul;21(7):482-8. doi: 10.1258/ijsa.2010.010070. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05060471 -
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
|
Phase 2 | |
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Completed |
NCT05518201 -
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
|
Phase 1 | |
Withdrawn |
NCT02857608 -
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
|
Phase 2 | |
Active, not recruiting |
NCT02546973 -
Quality of Life in Patients With Anal Cancer
|
||
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00550589 -
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
|
Phase 2 | |
Completed |
NCT00324415 -
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
|
Phase 2 | |
Terminated |
NCT00568425 -
QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
|
||
Terminated |
NCT00267787 -
Molecular Genetic and Pathological Studies of Anal Tumors
|
||
Completed |
NCT00066430 -
Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
|
Phase 1 | |
Completed |
NCT04083053 -
High-Resolution Anoscopy Perceived Discomfort Study
|
N/A | |
Completed |
NCT03506529 -
Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
|
||
Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
Recruiting |
NCT04857528 -
Detecting HPV DNA in Anal and Cervical Cancers
|
||
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01937780 -
Anal Cancer Radiotherapy Study
|